The Biotech Growth Trust PLC
BIOG.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.02 | 0.10 | 0.01 |
| FCF Yield | -2.14% | -1.22% | -1.87% | -3.54% |
| EV / EBITDA | -2.78 | 0.00 | 0.00 | -37.64 |
| Quality | ||||
| ROIC | -36.48% | 18.80% | -10.47% | -46.90% |
| Gross Margin | 101.71% | 97.08% | 114.11% | 102.29% |
| Cash Conversion Ratio | 0.06 | -0.06 | 0.14 | 0.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 27.19% | – | – | – |
| Free Cash Flow Growth | -19.95% | 28.00% | 55.33% | -132.39% |
| Safety | ||||
| Net Debt / EBITDA | 0.10 | 0.00 | 0.00 | -2.96 |
| Interest Coverage | -62.28 | 68.61 | -46.33 | -1,141.46 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -111.57 | 39.94 | -431.07 | -34.36 |